Corrigendum to: Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week Free

This is a corrigendum to: Raffaele De Caterina, Stefan Agewall, Felicita Andreotti, Dominick J Angiolillo, Deepak L Bhatt, Robert A Byrne, Jean-Philippe Collet, John Eikelboom, Alexander C Fanaroff, C Michael Gibson, Andreas Goette, Gerhard Hindricks, Gregory Y H Lip, Tatjana Potpara, Holger Thiele, Renato D Lopes, Mattia Galli, Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week, European Heart Journal, 2022; ehac294, https://doi.org/10.1093/eurheartj/ehac294

In the originally published version of this manuscript, the following sentence in the Graphical abstract was incorrect:

Five major trials in this field including almost 12,000 patients showed that 1-week TT followed by OAC plus DAPT reduced bleeding with a similar rate of ischaemic events compared with 6-12 months TT.

This has been corrected to:

Five major trials in this field including almost 12,000 patients showed that 1-week TT followed by OAC plus SAPT reduced bleeding with a similar rate of ischaemic events compared with 6-12 months TT.

In addition, there was an error in the first sentence of legend of Figure 2. The erroneous sentence read:

Overestimation of the safety of double versus triple antithromotic therapy in randomised controlled trials as opposed to the real-world setting.

This has been corrected to:

Overestimation of the safety of double versus triple antithrombotic therapy in randomised controlled trials as opposed to the real-world setting.

An erroneous word “show?” was deleted from authors' affiliations under “Pro” and “Contra.”